Navigation Links
NEUMANN Diagnostics' Automated Cervical Cancer Test Achieves Exceptional Accuracy
Date:2/3/2016

BUDAPEST, Hungary, Feb. 3, 2016 /PRNewswire/ -- Molecular assays developer NEUMANN Diagnostics Ltd. today unveiled its CONFIDENCE™ molecular test portfolio setting a new standard in cervical cancer screening.

The tests demonstrated superior accuracy achieving very high sensitivity without compromising on specificity. In HPV-positive women aged 25 years or older sensitivity for severe cervical dysplasia or worse condition at baseline was 91.94% (95% CI 82.17 – 97.33) meanwhile specificity in the same group was 74.35% (95% CI 71.78 – 76.81).

The CONFIDENCE™ test portfolio (consisting of a human papillomavirus test (HPV) and an epigenetic biomarker) was evaluated in a multicentre clinical trial involving over 7,000 cervical samples collected from over 6,000 women. This clinical trial makes the CONFIDENCE™ biomarker the most validated epigenetic biomarker for cervical cancer diagnostics.

"We are very pleased with the results of the study. This is the first highly accurate screening method in the world with fully automated evaluation," said Miklós Nyíri, managing director of NEUMANN.

Initially NEUMANN intends to introduce the test to complement current screening methods. Its biomarker test can help substantially increase the sensitivity of Pap testing without impacting specificity. 

"What is needed the most today is increasing sensitivity of the current screening system and finding women in need of treatment as early as possible" – said Nyíri. "We recommend using the CONFIDENCE™ tests on all samples which did not get a severe dysplasia diagnosis – because there is a potentially undetected underlying disease."

In the clinical trial the CONFIDENCE™ tests found severe cases up to 12 months earlier than Pap smear.

When no sign of malignancy is found with conventional methods, NEUMANN's test, with a proprietary algorithm, can establish the individual risk of each woman for cervical pre-cancer or cancer.  

One of the first clients of NEUMANN for its HPV diagnostics technology is the Synlab GenoID Molecular Laboratory, part of the Synlab Group, Europe's largest laboratory network.

The aim of NEUMANN is to prove its method can be a standalone solution for cervical cancer screening in any environment – including in developing countries where cytopathology is non-existent.

About NEUMANN

NEUMANN develops automated diagnostic testing systems for cancer screening and STDs. The company is majority owned by the X-Ventures Beta Venture Capital Fund co-financed by Hungarian private investors and the EIB in the Joint European Resources for Micro to Medium Enterprises (Jeremie) program.

www.neumanndx.com

Contact:

Ms Anna Faludi
email: anna.faludi@x-ventures.hu
tel: +36-70-454-3254

 

Photo - http://photos.prnewswire.com/prnh/20160128/326991   
Logo - http://photos.prnewswire.com/prnh/20160128/326990LOGO

 


'/>"/>
SOURCE NEUMANN
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Der automatisierte Gebärmutterhalskrebs-Test von NEUMANN Diagnostics erreicht eine außergewöhnliche Genauigkeit
2. MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013
3. Alzheimer Market: Drugs, Therapeutics & Diagnostics Research Reports
4. Apnix Sleep Diagnostics Announces New Houston Sleep Apnea Treatments
5. MGC Diagnostics Corporation Reports 2013 Second Quarter Operating Results
6. QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics
7. Accelerate Diagnostics Announces Plans For Rights Offering To Stockholders
8. In Vitro Diagnostics - A Global Market Overview
9. Global In Vitro Diagnostics Markets Outpace Pharma Industry Growth, finds Frost & Sullivan
10. Quest Diagnostics CEO Steve Rusckowski Reaffirms Full-Year 2013 Guidance At The Jefferies 2013 Global Healthcare Conference
11. Quest Diagnostics and Hologic Form Strategic Alliance to Improve Womens Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2018)... ... August 15, 2018 , ... ... announced today that athenahealth, a leading provider of network-enabled services for hospital ... for its IQR program requirements. The Drummond-certified program will enable athenahealth to ...
(Date:8/15/2018)... ... 15, 2018 , ... During a special ceremony at the ... Illinois, was named the grand prize winner of the 2018 IsaBody Challenge®. The ... a global health and wellness company providing nutrition and lifestyle solutions. , ...
(Date:8/14/2018)... ... 2018 , ... Altamonte Springs-based Adventist Health System, one of ... more than 80,000 employees, today announced that it will soon become AdventHealth. With ... and identifiable national system of care for every stage of life and ...
Breaking Medicine Technology:
(Date:8/14/2018)... ... August 14, 2018 , ... ... announced new leadership roles for healthcare executives Simon Frisch and Chris Weinstein, who ... respectively. They assume their roles at a time of tremendous growth for the ...
(Date:8/14/2018)... ... August 14, 2018 , ... Ross A. Clevens, MD, FACS is ... at Clevens Face and Body Specialists. Dr. Clevens is known for introducing innovative techniques ... and Merritt Island offices. Along with his associate, Amy Simon, MD, FACS, Dr. Clevens ...
(Date:8/11/2018)... ... August 10, 2018 , ... Georgia ... procedures to metro Atlanta. Drs. Brent Sharpe and Froylan Gonzalez recently widened that ... in Braselton. , On June 27, the physicians combined their expertise to perform ...
(Date:8/9/2018)... ... August 09, 2018 , ... Balboa Horizons, an industry leader ... that substance abuse providers must pass in order to advertise on Google. Balboa’s ... to help.” , Helping people is what Balboa Horizons is all about. ...
(Date:8/7/2018)... ... August 07, 2018 , ... Josh Sprague, Founder and CEO ... video preview for the upcoming Leadville 100 MTB. , Accompanied by colleague Marvin ... what he has called “one of the most iconic mountain bike race courses in ...
Breaking Medicine News(10 mins):